National AML Clinical Guidelines Now Available

These guidelines were funded by the Department of Health and Aged Care, facilitated by HSANZ and the Blood Cancer Taskforce, supported by the Leukaemia Foundation.

Why These Guidelines Matter:

• Improve Patient Outcomes: Standardised, evidence-based recommendations for optimal care.
• Support Clinical Decisions: practical, evidence-based treatment pathways.
• Enhance Consistency in Care: Reduce unwarranted variations in care.

What’s Inside:

• Clear treatment pathways for Australian clinicians.
• Pharmaceutical strategies(induction, consolidation, and maintenance therapy.)
• Expert-driven antimicrobial prophylaxis recommendations.
• Insights on drug approvals, emerging therapies and access challenges

Access the Guidelines: Available exclusively for healthcare professionals here.

We encourage you to share this resource with your colleagues and peers to help promote consistent, high-quality AML care across all clinical settings.

Background & Purpose: These guidelines were established through collaboration with leading haematologists, infectious diseases specialists, and key haematology organisations. They align with NHMRC standards to support clinicians in delivering high-quality, standardised AML care across Australia.

Questions: For questions contact Fiona Haigh, project manager, via [email protected].